Valink Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $11.8M

  • Investors
  • 18

Valink Therapeutics General Information

Description

Developer of a modular protein platform designed to facilitate the scalable discovery of bi-specific biologics. The company's platform uses robotic screening and big data analysis to discover bispecific lead assets with new modes of action to construct complex bispecific and multispecific biologics and deploys a scalable pipeline for internal and collaborative discovery of bispecific antibodies, from protein design to robotic screening and AI analysis, enabling medical practitioners to provide new alternatives to cancer treatment.

Contact Information

Website
www.valinktx.com
Formerly Known As
LiliumX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Imperial Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom
Primary Industry
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • Imperial Translation & Innovation Hub
  • 84 Wood Lane
  • London W12 0BZ
  • England, United Kingdom

Valink Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Valink Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 20-Oct-2025 $11.8M Completed Pre-Clinical Trials
7. Early Stage VC 01-Jan-2024 Completed Pre-Clinical Trials
6. Seed Round 03-Nov-2023 Completed Pre-Clinical Trials
5. Angel (individual) 01-Feb-2022 Completed Pre-Clinical Trials
4. Accelerator/Incubator 01-Jan-2022 Completed Pre-Clinical Trials
3. Seed Round 10-May-2021 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2021 $125K $125K Completed Pre-Clinical Trials
1. University Spin-Out 11-Dec-2020 Completed Startup
To view Valink Therapeutics’s complete valuation and funding history, request access »

Valink Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view Valink Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Valink Therapeutics Patents

  • 10

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Valink Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202214235-D0 Multivalent proteins and screening methods Inactive 28-Sep-2022
WO-2024069180-A2 Multivalent proteins and screening methods Inactive 28-Sep-2022
WO-2024069180-A3 Multivalent proteins and screening methods Inactive 28-Sep-2022
CA-3212924-A1 Multivalent proteins and screening methods Pending 24-Mar-2021
GB-202316256-D0 Multivalent proteins and screening methods Active 24-Mar-2021 C07K14/315
To view Valink Therapeutics’s complete patent history, request access »

Valink Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Valink Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
LongeVC Venture Capital Minority
Oxford Science Enterprises Venture Capital Minority
Saras Capital Hedge Fund Minority
P53 Venture Capital Minority
Redalpine Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

Ready to get started?

Request a free trial

Valink Therapeutics FAQs

  • When was Valink Therapeutics founded?

    Valink Therapeutics was founded in 2020.

  • Where is Valink Therapeutics headquartered?

    Valink Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Valink Therapeutics?

    Valink Therapeutics has 16 total employees.

  • What industry is Valink Therapeutics in?

    Valink Therapeutics’s primary industry is Drug Discovery.

  • Is Valink Therapeutics a private or public company?

    Valink Therapeutics is a Private company.

  • What is Valink Therapeutics’s current revenue?

    The current revenue for Valink Therapeutics is .

  • How much funding has Valink Therapeutics raised over time?

    Valink Therapeutics has raised $20.5M.

  • Who are Valink Therapeutics’s investors?

    LongeVC, Oxford Science Enterprises, Saras Capital, P53, and Redalpine are 5 of 18 investors who have invested in Valink Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process